Physician profile
Mark Williams
NPI 1508947276
$493.14
in general payments reported to CMS, 2019-2025
10 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.09 · 2022: $55.06 · 2023: $42.50 · 2024: $209 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $145.64 | 2024-2025 | Misight Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $98.73 | 2024-2025 | |
| Tarsus Pharmaceuticals, INC. | $73.12 | 2025 | Xdemvy |
| Alcon Vision LLC | $52.86 | 2022-2024 | Total30 |
| Lkc Technologies, INC. | $27.22 | 2024 | |
| Carl Zeiss Meditec USA, INC. | $25.71 | 2023 | Humphrey Hfa |
| Lombart Brothers, INC. | $22.74 | 2024 | Opd-III |
| Novartis Pharmaceuticals Corporation | $21.36 | 2022 | |
| Bausch & Lomb Americas INC. | $14.67 | 2022 | |
| Abb Con-Cise Optical Group LLC | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.